# US 2026/0234667 A1 · Nucleic Acids Encoding TGF-Beta Inhibitor and IL-12 and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0234667 A1
- Document ID: US20260234667A1
- Status: Published application
- Kind: A1
- Application number: 19/181,919
- Filed: 2025-04-17
- Published: 2026-08-13
- Earliest claimed: 2022-10-19
- Assignees: KaliVir Immunotherapeutics, Inc.
- Applicants: KaliVir Immunotherapeutics, Inc.
- Inventors: Stephen Howard THORNE; Mingrui ZHANG
- Web page: https://patentgrep.com/patent/US20260234667A1

## CPC

- C12N 15/86: Viral vectors
- C12N 15/8636: {Vaccina virus vectors}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C07K 14/495: Transforming growth factor [TGF]
- C07K 14/5434: {IL-12}
- C07K 14/7158: {for chemokines}
- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/02: containing a signal sequence
- C12N 2710/24132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2830/34: being a transcription initiation element
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides for a nucleic acids encoding for a transforming growth factor inhibitor and IL-12. Further provided herein are nucleic acids encoding for chemokine receptor CXCR3. Additionally described herein are oncolytic viruses comprising the nucleic acids described herein. Compositions described herein are further described for use in the treatment of cancer.

## Claims

### Claim 1

A composition, wherein the composition comprises:
a vector, wherein the vector comprises:
an exogenous nucleic acid comprising a sequence encoding for a cytokine or a functional variant thereof;
an exogenous nucleic acid comprising a sequence encoding for a chemokine receptor or a functional variant thereof; and
a first promoter region, wherein the first promoter region is upstream to the sequence encoding for the chemokine receptor and provides for expression of the chemokine receptor prior to expression of the cytokine.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the encoded chemokine receptor comprises at least one of: a CXC receptor, a CC receptor, a CX3C receptor, an XC receptor, a functional fragment thereof, a functional variant thereof, or any combinations thereof.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the encoded chemokine receptor comprises at least one of: CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CCR11, CX3CR1, XCR1, a functional fragment thereof or a functional variant thereof, or any combinations thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the encoded chemokine receptor comprises CXCR3, and wherein the encoded chemokine receptor comprises an amino acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 43 or SEQ ID NO: 42.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the first promoter region comprises an early promoter, and wherein the early promoter comprises any one of A52R, pB8, mH5, I4L, LEO, pF11, I3L, P7.5, TK promoter, F7L, H5R, a short synthetic promoter (SSP) or any variation or combination thereof.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the early promoter comprises the A52R promoter.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the encoded cytokine comprises IL-12 or a functional variant thereof.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the encoded IL-12 comprises an amino acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to either one of SEQ ID NO: 15 or SEQ ID NO: 12.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the sequence encoding for the IL-12 comprises a nucleic acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to either one of SEQ ID NO: 66 or SEQ ID NO: 64.

### Claim 10 (depends on 1)

The composition of claim 1, further comprising an exogenous nucleic acid comprising a sequence encoding for a Transforming growth factor beta (TGF-beta) activity inhibitor; wherein the first promoter region provides for expression of the chemokine receptor prior to expression of the TGF-beta activity inhibitor.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the encoded TGF-beta activity inhibitor comprises a TGF-beta dominant negative, a TGF-beta receptor dominant negative, a protein that binds TGF-beta, or a protein that binds to a TGF-beta receptor.

### Claim 12 (depends on 11)

The composition of claim 11, wherein the encoded protein that binds TGF-beta receptor is a protein comprising a domain of TGF-beta, and wherein the encoded protein comprising a domain of TGF-beta comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 1-9.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the sequence encoding for the Transforming growth factor beta (TGF-beta) activity inhibitor comprises a nucleic acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 67.

### Claim 14 (depends on 11)

The composition of claim 11, wherein the encoded protein that binds to TGF-beta receptor is a TGF-beta fusion protein, and wherein the TGF-beta fusion protein comprises a human IgE signal peptide and a TGF-beta variant 2 (TGFbv2).

### Claim 15 (depends on 14)

The composition of claim 14, wherein the human IgE signal peptide comprises an amino acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 37.

### Claim 16 (depends on 14)

The composition of claim 14, wherein the TGFbv2 comprises an amino acid sequence having at least 85%, 90%, 95%, 99%, or 100% sequence identity to SEQ ID NO: 8.

### Claim 17 (depends on 10)

The composition of claim 10, wherein the sequence encoding for the cytokine comprises a second promoter region that provides for expression of the cytokine, and wherein the sequence encoding for the TGF-beta activity inhibitor comprises a third promoter region that provides for expression of the TGF-beta activity inhibitor, and wherein each of the second and third promoter regions comprise a late promoter comprising any one of SSP, P7.5, P28, P135, TK promoter, E/L, F7L, H5R, H1L, A1L, J3R, E4L, I1L, I5L, I7L, T7, I2L, FP4b, ATI, P11, PFL1, PH5, L4R, 28 kDa promoter, or any variation or combination thereof.

### Claim 18 (depends on 17)

The composition of claim 17, wherein the second promoter region comprises a P135 promoter, and wherein the third promoter region comprises a P7.5 promoter.

### Claim 19 (depends on 10)

The composition of claim 10, wherein the exogenous nucleic acid encoding for a cytokine or a functional variant thereof, the exogenous nucleic acid encoding for the TGF-beta activity inhibitor, and the exogenous nucleic acid encoding for the chemokine receptor or functional variant thereof are located on a single genome.

### Claim 20 (depends on 1)

The composition of claim 1, wherein the vector is an oncolytic virus, and wherein the oncolytic virus comprises at least one genome modification.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the at least one modification comprises mutation or deletion of at least one gene selected from the group consisting of: Thymidine Kinase (TK)21, F13L, A36R, A34R, A33R, A52R, B5R, B8R, B18R, SPI-1, SPI-2, B15R, VGF, E3L, K3L, A41L, K7R, or N1L, a functional fragment thereof, or any combination thereof.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the at least one modification comprises a deletion of genes A52R and TK.

### Claim 23 (depends on 20)

The composition of claim 20, wherein the oncolytic virus is a poxvirus, an adeno associated virus, an adenovirus, a reovirus, a lentivirus, a herpes simplex virus, a vesicular stomatitis virus, a mengovirus, a myxoma virus, Newcastle disease virus, measles virus, or polio virus.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the poxvirus is a vaccinia virus, and wherein the vaccinia virus is a Western Reserve strain.

### Claim 25

A nucleic acid molecule, wherein the nucleic acid molecule comprises:
an insertion at an A52R locus comprising a sequence as set forth in SEQ ID NO: 88;
an insertion at a TK gene locus comprising a sequence as set forth in SEQ ID NO: 85.

### Claim 26 (depends on 1)

A pharmaceutical composition, wherein the pharmaceutical composition comprises:
the composition of claim 1; and
a pharmaceutically acceptable excipient.

### Claim 27 (depends on 26)

A method for treatment of cancer comprising administering to a subject having cancer the pharmaceutical composition of claim 26 in an amount sufficient for treatment of a cancer.
